These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 38612657)

  • 1. Huntington's Disease: Complex Pathogenesis and Therapeutic Strategies.
    Tong H; Yang T; Xu S; Li X; Liu L; Zhou G; Yang S; Yin S; Li XJ; Li S
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration.
    Lu B; Palacino J
    FASEB J; 2013 May; 27(5):1820-9. PubMed ID: 23325320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease.
    Tabrizi SJ; Ghosh R; Leavitt BR
    Neuron; 2019 Mar; 101(5):801-819. PubMed ID: 30844400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hope for Huntington's disease patients: first clinical gene silencing study in progress].
    Rollnik JD
    Fortschr Neurol Psychiatr; 2017 Aug; 85(8):463-466. PubMed ID: 28841744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.
    Carbo M; Brandi V; Pascarella G; Staid DS; Colotti G; Polticelli F; Ilari A; Morea V
    Int J Mol Med; 2019 Dec; 44(6):2223-2233. PubMed ID: 31638189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dermal Fibroblast Cell Line from a Patient with the Huntington's Disease as a Promising Model for Studying Disease Pathogenesis: Production and Characterization.
    Kraskovskaya N; Koltsova A; Parfenova P; Shatrova A; Yartseva N; Nazarov V; Devyatkina E; Khotin M; Mikhailova N
    Biochemistry (Mosc); 2024 Jul; 89(7):1239-1250. PubMed ID: 39218021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease.
    Layburn FE; Tan AYS; Mehrabi NF; Curtis MA; Tippett LJ; Turner CP; Riguet N; Aeschbach L; Lashuel HA; Dragunow M; Faull RLM; Singh-Bains MK
    Neurobiol Dis; 2022 Nov; 174():105884. PubMed ID: 36220612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
    Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
    J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
    Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
    Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
    Miniarikova J; Evers MM; Konstantinova P
    Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large animal models for Huntington's disease research.
    Han B; Liang W; Li XJ; Li S; Yan S; Tu Z
    Zool Res; 2024 Mar; 45(2):275-283. PubMed ID: 38485497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant huntingtin expression in microglia is neither required nor sufficient to cause the Huntington's disease-like phenotype in BACHD mice.
    Petkau TL; Hill A; Connolly C; Lu G; Wagner P; Kosior N; Blanco J; Leavitt BR
    Hum Mol Genet; 2019 May; 28(10):1661-1670. PubMed ID: 30624705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gedunin Degrades Aggregates of Mutant Huntingtin Protein and Intranuclear Inclusions via the Proteasomal Pathway in Neurons and Fibroblasts from Patients with Huntington's Disease.
    Yang W; Xie J; Qiang Q; Li L; Lin X; Ren Y; Ren W; Liu Q; Zhou G; Wei W; Saiyin H; Ma L
    Neurosci Bull; 2019 Dec; 35(6):1024-1034. PubMed ID: 31432317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington's disease.
    Shafie A; Ashour AA; Anwar S; Anjum F; Hassan MI
    Arch Pharm Res; 2024 Jun; 47(6):571-595. PubMed ID: 38764004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
    Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
    Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
    Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
    J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huntington's disease: new hope for therapeutics.
    McMurray CT
    Trends Neurosci; 2001 Nov; 24(11 Suppl):S32-8. PubMed ID: 11881743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unraveling the Puzzle of Therapeutic Peptides: A Promising Frontier in Huntington's Disease Treatment.
    Ahamad S; Bano N; Khan S; Hussain MK; Bhat SA
    J Med Chem; 2024 Jan; 67(2):783-815. PubMed ID: 38207096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.